Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
JUNCTION CITY, Kan., Oct. 23, 2017 -- Ventria Bioscience Inc. today announced a $4.2 million grant from the Bill & Melinda Gates Foundation to fund development of efficient biomanufacturing for new therapeutics targeting Enterotoxigenic Escherichia coli (or ETEC), a leading bacterial cause of diarrhea in the developing world. ETEC accounts for an estimated 280 million to 400 million cases of diarrhea a year in children under five and an estimated 157,000 deaths per year. The bacterial infection also is implicated in travelers’ diarrhea.
Funding by the Gates Foundation will enable Ventria to develop its platform to produce potential ETEC treatments using Ventria’s cost-effective, scalable and safe ExpressTec technology.
“We are very pleased to receive this funding from the Bill & Melinda Gates Foundation to fight ETEC diarrheal disease, which causes widespread misery, especially among young children in lower-income countries. This initiative aims to develop a new kind of oral treatment that could be delivered economically on a large scale for use in children or adults,” said Scott E. Deeter, President and Chief Executive Officer of Ventria. “We have proven the effectiveness of our ExpressTec system for biomanufacturing synthetic colostrum proteins, such as lactoferrin and lysozyme. This new application in the global fight against ETEC adds to Ventria’s pipeline of projects with the potential to make a real difference in people’s health.”
Seymour Fein, M.D., Chief Medical Officer of Ventria, added: “The burden of gastrointestinal and diarrheal diseases in the developing world is devastating, causing hundreds of millions of people to suffer, taking the lives of the least fortunate, and draining the resources of caregivers in Africa, Asia and Latin America. ETEC infection cries out for an effective treatment that can be delivered on a large scale in areas struggling with poverty, and the Gates Foundation initiative brings hope to patients and societies afflicted by this disease. Ventria’s expertise in producing safe, high-quality proteins adds an important component to this global public health effort.”
About Ventria Bioscience Inc.
Ventria Bioscience is a biopharmaceutical company with a product pipeline targeting unmet medical needs. Ventria Bioscience’s proprietary ExpressTec biomanufacturing technology enables the development of new, safe and effective biologic products to treat gastrointestinal, autoimmune and infectious disease. For more information, visit www.Ventria.com.
For further information, contact:
Media inquiries: Dick Johnson, 913-649-8885, [email protected]
Partnering: [email protected]
